Cited by 110Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Aβ-amyloid and Tau Imaging in Dementia

Villemagne, Victor L., Doré, Vincent, Bourgeat, Pierrick, Burnham, Samantha C., Laws, Simon, Salvado, Olivier, Masters, Colin L., Rowe, Christopher C.·2017·Seminars in Nuclear Medicine

Abstract

The introduction of in vivo imaging of Aβ-amyloid (Αβ) pathology more than a decade ago, transformed the assessment of Alzheimer disease (AD) allowing the evaluation of Aβ deposition over time by providing highly accurate, reliable, and reproducible quantitative statements of regional or global Aβ burden in the brain to the extent that Aβ imaging has already been approved for clinical use and is being used for both patient recruitment and outcome measure in current anti-Αβ therapeutic trials. Aβ imaging studies have deepened our insight into Aβ deposition, showing that Aβ accumulation is a slow and protracted process extending for more than two decades before the onset of the clinical phenotype. Although cross-sectional evaluation of Αβ burden does not strongly correlate with cognitive impairment in AD, Αβ burden does correlate with memory impairment and a higher risk for cognitive decline in the aging population and mild cognitive impairment subjects. These associations suggest that Αβ deposition is not a benign process. The recent addition of selective tau imaging will allow to elucidate if these effects are directly associated with Αβ deposition or if they are mediated, in toto or in parte, by tau as it spreads out of the mesial temporal lobe into neocortical association areas. The combination of Aβ and tau imaging studies would likely help elucidate the relationship or interplay between the two pathologic hallmarks of the disease. Longitudinal observations to assess their potential independent or synergistic, sequential or parallel effects on cognition, disease progression, and other disease-specific biomarkers of neurodegeneration would be required to further clarify the respective role of Αβ and tau deposition play in the course of AD.

Integrity signals

Registry

Crossref · 10.1053/j.semnuclmed.2016.09.006

Cites

234 of 234 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aβ-induced cytokines promote tau hyperphosphorylation and pathology, creating a self-perpetuating loop that worsens disease.

    “Similarly, Aβ-induced cytokines promote tau hyperphosphorylation and pathology, thus initiating a self-perpetuating loop that culminates in worsening disease44,45.”

    From Microglia in neurodegeneration (2018) · cites this paper as [45]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C.
Affiliations
  • The University of Melbourne (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
  • Edith Cowan University (AU)
Corresponding author
Villemagne, Victor L.
Venue
Seminars in Nuclear Medicine
Publisher
Elsevier BV
Published
2017-01
Volume
47
Issue
1
Pages
75-88
ISSN
0001-2998 (ISSN-L)
OpenAlex
W2530117917
Cited by
110
References
234
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 8 · 2021: 17 · 2020: 8 · 2019: 14 · 2018: 17 · 2017: 22
FWCI
2.52
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
Funders
National Health and Medical Research Council of Australia
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
amyloid-beta imaging, tau imaging, Alzheimer's disease, dementia, amyloid-beta deposition, tau pathology, mild cognitive impairment, cognitive decline, memory impairment, disease progression, neurodegeneration biomarkers
MeSH terms
Dementia, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Molecular Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review